Back to Search

A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer

  • Protocol Number: 202310120
  • Principal Investigator: Pachynski, Russell
  • Cancer Types: GU: Bladder, Kidney, Prostate, Testicular

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of JNJ-78278343 with the combination agent in Part 2 (dose expansion).

Protocol Interventions

Drug: JNJ-78278343, Drug: Cetrelimab, Drug: Cabazitaxel, Drug: Docetaxel, Drug: Apalutamide, Drug: Enzalutamide, Drug: Darolutamide, Drug: Abiraterone acetate plus prednisone (AAP)